ClinicalTrials.gg
RecruitingNCT05266521Updated Feb 7, 2024

Safety and Efficacy Assessment of Using the zLOCK Facet Stabilization System

An interventional study of zLOCK Facet Stabilization System in Low Back Pain, sponsored by ZygoFix. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by ZygoFix · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2021, registered Feb 2022).
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.

Planned enrollment
36th of 54
80 · median 128
Started
2021
with 3 others
No phase
31 of 59
3 open now
Registered
45th of 59
by date

Among the 59 studies in Low Back Pain with a site in Germany, this one is the 36th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 with no phase, and was the 45th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Low Back Pain with a site in Germany, or all of them as a file.
02

Study summary

The zLOCK Facet Stabilization System is a fixation device intended to provide posterior stability in the lumbar spine fusion procedure. The system can be placed either as an adjunct to an inter-vertebral anterior cage or as stand-alone with/ without additional decompression of the dural sac or nerve roots as appropriate for the specific patient and surgeon's discretion. The zLOCK implant is placed inside the facet to stabilize the motion and enhance the bony fusion of the joint. The zLOCK Facet Stabilization System is intended for single-level stabilization of a spinal motion segment in order to promote bony fusion of the joint. The zLOCK system is indicated for use from L1-L2 to L5-S1 joints.

The zLOCK implant is inserted into the facet joint space while adapting to the joint's changing geometry. Stabilization is achieved by a firm grip of each joint bone and resisting any relative motion. The zLOCK implant is placed percutaneously and requires only one incision per side, thereby reducing the invasiveness procedure duration and shortening the recovery period.

This pivotal study was designed in order to assess the safety and effectiveness of the zLOCK system.

03

Conditions studied

  • Low Back Pain

Keywords

  • Stabilization
  • Facet arthritis
  • Spondylolisthesis
  • Stenosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is scheduled for spine surgery with at least one of the following:

    • Degenerative Spondylolisthesis grade 1;
    • Mild to Moderate stenosis;
    • Degeneration of the facets.
  2. When used stand-alone disc height should be maximum 50% of the adjacent disc height.
  3. 18\< Age \<75
  4. Weight \< 100Kg
  5. Signed form
  6. At least 3 months of unsuccessful conventional treatments

Exclusion criteria

Exclusion Criteria:

  1. Fusion procedure performed or required in more than one motion segment.
  2. Acute or chronic spinal infections.
  3. Osteoporosis when used in adjunct to an anterior interbody cage (DEXA \< -2.5).
  4. Absence of posterior spinal elements including the pedicle, pars interarticularis, facet joints, spinous process and the majority of the lamina which make it unstable or not possible to place.
  5. Any entity or conditions that totally preclude the possibility of fusion, i.e. cancer or kidney dialysis.
  6. Obesity ( ≥30)
  7. Unilateral application of device, except in combination with anterior interbody cages.
  8. Known sensitivity to Titanium.
  9. Alcoholism, or drug abuse
  10. Subject with a cardiac pacemaker or other implanted electro medical device
  11. Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of that do not practice medically acceptable methods of )
  12. Concurrent participation in another clinical trial using any drug or device.
  13. Mental disorders.
  14. Tumor
  15. Fracture or other instabilities of the posterior elements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    zLock Facet Locking Implant System

    Device: zLOCK Facet Stabilization System zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains

    Device: zLOCK Facet Stabilization System

Interventions

  • DevicezLOCK Facet Stabilization System

    zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events as assessed by paucity of device related reoperation

    The safety of the zLOCK Facet Implant System will be established based on the paucity of device-related reoperations.

    Time frame: 3 months

Secondary outcomes

  1. Change in pain level measured by Visual Analog Score for pain

    The efficacy assessment of the ZygoFix Facet stabilization System will be established by change in pain level .

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • MedizinischenFakultät der Universität Rostock
    Rostock, 18055, Germany
    Recruiting
  • AOU Policlinico "Paolo Giaccone"
    Palermo, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jan 2025, 38 months after the start.

Of 56 industry-sponsored interventional studies with no phase under Low Back Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 38 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2022
First posted
Mar 4, 2022
StartActual
Nov 7, 2021
Primary completionEst.
Jan 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05266521
Lead sponsor
ZygoFix
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Nov 7, 2021
Primary completion
Jan 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Hanna Levy, Dr.
Contact
hanna@qsitemed.com
+972522824966
Hanna Levy, Dr.
study director · ZygoFix

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion